Lung Cancer Trial, Recruiting NCT06572540 Sponsor: Jiayuan Sun Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT06572540
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are over 18 years old
  • People who have been diagnosed with primary peripheral lung cancer (a specific type of lung cancer located toward the outer part of the lung), confirmed by a tissue test (pathology), at an early stage (called stage IA, T1N0M0) — this includes people who have developed a new or separate lung cancer after previous surgery
  • People whose lung tumour has been assessed as suitable for treatment using both CT-guided and bronchoscopy-guided ablation (procedures that use imaging and a small camera to guide targeted treatment)
  • People who are not suitable for surgery, or who have chosen not to have surgery, and who agree to receive ablation as the first treatment and have signed a consent form

Who may not be able to join:

  • People with a low platelet count, serious bleeding problems, or blood clotting disorders that cannot be corrected quickly
  • People with severe scarring of the lung tissue (pulmonary fibrosis) or high blood pressure in the lung's blood vessels (pulmonary arterial hypertension)
  • People who have an active infection or radiation-related inflammation near the tumour, an uncontrolled skin infection at the planned treatment site, a body-wide infection, or a high fever above 38.5°C
  • People with serious problems affecting the liver, kidneys, heart, lungs, or brain, or with severe anaemia, dehydration, or significant nutritional problems that cannot be corrected or improved quickly
  • People with pleural effusion (fluid around the lungs) that is not well controlled
  • People who have been taking blood-thinning or anti-platelet medications (with some exceptions such as dabigatran or rivaroxaban) and have not stopped taking them at least 5–7 days before the procedure
  • People with a physical functioning score above 2 on a standard scale used to measure how much a person's illness affects their daily abilities (confirm with trial site)
  • People who have another cancer that has spread widely through the body, with an expected survival of less than 6 months
  • People with a history of episodic (recurring) psychosis (serious mental health episodes)
  • People who are pregnant, or who plan to become pregnant during the study period
  • People who have taken part in, or are currently taking part in, another clinical trial within the past 30 days
  • People who have any other condition that the trial investigators consider unsuitable for participation

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jiayuan Sun, PhD, Shanghai Chest Hospital

Phone: +86-021-22200000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Jiayuan Sun
Registry
ClinicalTrials.gov
Start date
1 September 2024
Est. completion
31 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Complete ablation rate at 12 months

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov